We could not find any results for:
Make sure your spelling is correct or try broadening your search.
L'OCRCVM permet la reprise de la négociation - APC Canada NewsWire VANCOUVER, BC, le 17 janv. 2023 VANCOUVER, BC, le 17 janv. 2023 /CNW/ - Reprise des négociations pour : Société :...
IIROC Trading Resumption - APC Canada NewsWire VANCOUVER, BC, Jan. 17, 2023 VANCOUVER, BC, Jan. 17, 2023 /CNW/ - Trading resumes in: Company: Advanced Proteome Therapeutics...
Suspension de la négociation par l'OCRCVM - APC Canada NewsWire VANCOUVER, BC, le 17 janv. 2023 VANCOUVER, BC, le 17 janv. 2023 /CNW/ - L'OCRCVM a suspendu la négociation des titres...
IIROC Trading Halt - APC Canada NewsWire VANCOUVER, BC, Jan. 17, 2023 VANCOUVER, BC, Jan. 17, 2023 /CNW/ - The following issues have been halted by IIROC: Company: Advanced Proteome Therapeutics...
L'OCRCVM permet la reprise de la négociation - APC Canada NewsWire VANCOUVER, BC, le 17 déc. 2020 VANCOUVER, BC, le 17 déc. 2020 /CNW/ - Reprise des négociations pour : Société :...
IIROC Trading Resumption - APC Canada NewsWire VANCOUVER, BC, Dec. 17, 2020 VANCOUVER, BC, Dec. 17, 2020 /CNW/ - Trading resumes in: Company: Advanced Proteome Therapeutics Corporati TSX-Venture...
Suspension de la négociation par l'OCRCVM - APC Canada NewsWire VANCOUVER, BC, le 17 déc. 2020 VANCOUVER, BC, le 17 déc. 2020 /CNW/ - L'OCRCVM a suspendu la négociation des...
IIROC Trading Halt - APC Canada NewsWire VANCOUVER, BC, Dec. 17, 2020 VANCOUVER, BC, Dec. 17, 2020 /CNW/ - The following issues have been halted by IIROC: Company: Advanced Proteome Therapeutics...
L'OCRCVM permet la reprise de la négociation - APC Canada NewsWire VANCOUVER, BC, le 9 juill. 2020 VANCOUVER, BC, le 9 juill. 2020 /CNW/ - Reprise des négociations pour : Société :...
IIROC Trading Resumption - APC Canada NewsWire VANCOUVER, BC, July 9, 2020 VANCOUVER, BC, July 9, 2020 /CNW/ - Trading resumes in: Company: Advanced Proteome Therapeutics Corporati TSX-Venture...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions